Amgen, Inc. (NASDAQ:AMGN)

uncertainty market evolution

RBC’s Top Quintile Quantitative Portfolio Stocks to Buy Now

Most firms we cover on Wall Street have quantitative strategies for their clients, and often they use similar formulas to arrive at what belongs in the top quintile versus the ...
Read Full Story »
Biotechnology word cloud

Do Layoffs in Biotech Send the Right Message?

Investors could be facing a new future in biotech. After years and years of growth and after massive gains in recent years, is it possible that biotech giants are simply ...
Read Full Story »
biotech

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

A brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The ...
Read Full Story »
Comfortable hospital bed

Deutsche Bank Raises Price Targets on Top Biotech and Health Care Stocks

With the second-quarter earnings coming fast and furious, and with another big week in front of investors, many of the top Wall Street firms that we cover are getting the ...
Read Full Story »
Biotechnology word cloud

4 Top Biotechs Expected to Beat Earnings Expectations

With earning season just starting to be in full gear, everybody on Wall Street is looking for the earnings angle, and it seems like almost every firm we cover here ...
Read Full Story »
Biotechnology word cloud

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

After the biotech stocks were absolutely crushed in the late winter and early spring, many of the top firms we cover on Wall Street were aggressive in their calls to ...
Read Full Story »
Stock Split Image

Will Celgene Trigger Other Biotech Stock Splits?

Celgene Corp. (NASDAQ: CELG) has decided to join the stock split game. Stock splits do not create any fundamental change on the surface, but the problem that Celgene has faced ...
Read Full Story »
biotech

Short Sellers Remain Vigilant Against Top Biotech Stocks

Short sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company ...
Read Full Story »
health care

Analyst Cancer and Biotech Stock Picks From ASCO

As the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty pharmaceutical companies making announcements and presenting clinical data. The biggest ...
Read Full Story »
The_Googleplex

Google Top Company for Pay and Benefits

Google Inc. (NASDAQ: GOOG) topped all companies in terms of best pay and benefits in a new survey by online jobs site Glassdoor. It adds to Google's prime spot on ...
Read Full Story »
DNA

Top Biotech Stocks for Cancer Cures From Cowen

The conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many ...
Read Full Story »
buy sell

Why Investors Are Not Chasing Gilead Endlessly Higher

By any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock on Wednesday. Gilead blew away earnings and revenue estimates. Its ...
Read Full Story »
biotech

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Gilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild ...
Read Full Story »
Biotechnology word cloud

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

Biotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is ...
Read Full Story »
Biotechnology word cloud

Who Bucked the Short Interest Trend in Biotech Stocks?

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many ...
Read Full Story »